The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer.

Published in: Expert review of pharmacoeconomics & outcomes research (2021)

The proposed MVBR model would provide a stronger economic incentive to develop add-on drugs.

Keyphrases